Global urinary incontinence therapeutics market set to reach $3.4 billion by 2017 after growing at CAGR of 3.5%
The worldwide urinary incontinence (UI) therapeutics market was worth around $2.5 billion in 2009. In 2001 the market was valued at $1.4 billion and it increased at an approximate compound annual growth rate (CAGR) of 7.8% from 2001 to 2009, according to a new report from GlobalData, which says that this market sector is expected to reach $3.4 billion by 2017 after growing at a CAGR of 3.5%.
Patent expiries will inhibit growth
The impending patent expiries of Pfizer's Detrol (tolterodine) and Novartis' Enablex (darifenacin hydrobromide) are the major reasons for the slow market growth expected from 2012 onwards, says the report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze